BioCentury
ARTICLE | Financial News

MPM, Versant launch gene therapy play Coda

September 12, 2018 1:08 PM UTC

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also participated.

Coda is developing gene therapies to express neurotransmitter receptors that are activated by undisclosed small molecules to treat neurological disorders. The company's initial focus is chronic neuropathic pain. ...